Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 19/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 18/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16649143 | 0.88 | HCRTR2 (0.56) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL16648804 | 0.87 | HCRTR2 (0.54) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL16867193 | 0.87 | HCRTR2 (0.54) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL16867191 | 0.85 | HCRTR1 (0.56) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL16867192 | 0.83 | HCRTR1 (0.57) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL16648859 | 0.83 | HCRTR2 (0.61) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL16649053 | 0.82 | HCRTR2 (0.61) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL16661690 | 0.79 | HCRTR2 (0.53) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL16648840 | 0.77 | HCRTR2 (0.55) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL16648852 | 0.76 | HCRTR2 (0.61) | HCRTR2HCRTR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2862860-B1 | 1,3-OXAZOLIDINE OR 1,3-OXAZINANE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-9266870-B2 | Heteroaromatic methyl cyclic amine derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266870-B2 | Heteroaromatic methyl cyclic amine derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266870-B2 | Heteroaromatic methyl cyclic amine derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20150183768-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150183768-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150183768-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| EP-2862860-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183768-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | HCRTR2, HCRTR1, HTR2B | HCRTR2 1/4885HCRTR1 2/4885CYP3A4 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.